Contraindicated (one)bortezomib will increase the level or result of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may perhaps improve mavacamten systemic publicity, causing heart failure on account of systolic dysfunction. chloramphenicol will enhance the degree or effect of bortezomib by impacting hepatic/intestin... https://davidw110lvg3.dailyblogzz.com/profile